Loading...
 

Volume 31, Issue 2, June 2020




Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2020;31(2):239-41
Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
Authors Information

1.Department of Rheumatology, Patras University Hospital, University of Patras Medical School, Patras, Greece

2. Department of Rheumatology, Agios Andreas Hospital, Patras, Greece

3. 4th Department of Internal Medicine Hippokration Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece

4. 3rd Department of Clinical Oncology, Theageneio Cancer Hospital, Thessaloniki, Greece

5. Oncology/Chemotherapy Unit, Agios Andreas Hospital, Patras, Greece

6. Department of Oncology, Patras University Hospital, University of Patras Medical School, Patras, Greece

Abstract

Background: Immune checkpoint inhibitors (ICI) are anti-cancer drugs that act by enhancing anti-tumour immunity. Due to their mechanism of action, they have been associated with immune related adverse events (Ir-AE), including musculoskeletal manifestations. Aim: To assess a) the prevalence, clinical and imaging (MRI) characteristics of ICI-induced musculoskeletal immune related adverse events (ir-AE) in a prospective manner, b) the potential association of musculoskeletal ir-AE with oncologic response and changes in the immune system at the level of soluble molecules (cytokines) as well as T/B cell subpopulations. Methods: This a multicentre prospective study. We plan to recruit all patients who are going to start treatment with ICI from October 2019 until October 2020 in all collaborating Oncology Departments. This study is consisted of a clinical and a laboratory arm. Results: The study is currently recruiting patients. Conclusions: We anticipate that this study will provide useful data regarding the clinical characteristics of ICI-induced musculoskeletal manifestations as well as potential predictive biomarkers.


https://doi.org/10.31138/mjr.31.2.239

This work is licensed under a Creative Commons Attribution 4.0 International License.

©Daoussis D, Melissaropoulos K, Dimitroulas T, Andreadis H, Christopoulou A, Douganiotis G, Makatsoris T, Koutras A, Georgiou P, Kalofonos H.